NEOREHAB: Neoadjuvant Rehabilitation for Optimal Surgery
Research type
Research Study
Full title
NEOREHAB: Neoadjuvant Rehabilitation for Optimal Surgery- a randomised feasibility study
IRAS ID
362485
Contact name
Fiona Matthews
Contact email
Sponsor organisation
University of Hull, Hull, UK
Duration of Study in the UK
2 years, 11 months, 30 days
Research summary
Curable surgical lung cancer patients are often elderly, current smokers and have medical comorbidities. Since March 2023, new treatment is offered involving chemo-immunotherapy before surgery which reported improved survival. However, 20% of patients are not able to undergo surgery and others suffer side effects.
To maximize the benefits of neoadjuvant regimen there is an urgent need to optimise patient’s health before, during and after surgery, to allow the advantages of immunotherapy to be translated into improved survival. Investigating guideline-recommended cardio-pulmonary fitness for surgery in this context is needed as it can identify predictors of fitness decline and surgical complications to select high-risk groups who will benefit most of exercise programme.
The NEOREHAB study will evaluate the feasibility of providing a hybrid exercise programme for patients undergoing neoadjuvant treatment for resectable lung cancer.
We’ll assess the effect of this intervention on Quality of Life, fitness for surgery, postoperative morbidity and serum inflammatory markers.REC name
Yorkshire & The Humber - Leeds East Research Ethics Committee
REC reference
26/YH/0117
Date of REC Opinion
10 Jul 2026
REC opinion
Further Information Favourable Opinion